73
Participants
Start Date
November 9, 2022
Primary Completion Date
August 7, 2025
Study Completion Date
August 7, 2025
Poteligeo
Poteligeo treatment will be used as prescribed by the Investigator in accordance with the terms of the reimbursed indication within the relevant country. The assignment of the patient to a particular therapeutic strategy falls within current practice and the prescription of Poteligeo is clearly separated from the decision to include the patient in the study.
Colombia University Medical Center, New York
Sheikh Shakhbout Medical City, Abu Dhabi
The Johns Hopkins University School of Medicine, Baltimore
Inova Dwight and Martha Schar Cancer Institute, Fairfax
Washington University School of Medicine, St Louis
Fred Hutchinson Cancer Center, Seattle
Azienda Ospedaliero Universitaria Ospedali Riuniti Do Ancona, Ancona
IRCCS A.O.U. Policlinico S. Orsola - Malpighi, Bologna
Azienda Ospedaliero- Universitaria Careggi, Florence
Ematologia Policlinico di Milano, Milan
IFO-San Gallicano IRCCS, Rome
Universita Cattolica del Sacro Cuore - Policlinico Universitario Agostino Gemelli, Rome
Leids Universitair Medisch Centrum (LUMC), Leiden
Hospital Del Mar, Barcelona
Hospital Universitari de Bellvitge, Barcelona
Clatterbridge Hospital - Wirral University Teaching Hospital Nhs Foundation Trust, Bebington
University Hospital Birmingham, Birmingham
The Christie NHS Foundation Trust, Manchester
Nottingham University Hospitals NHS Trust - Nottingham City Hospital, Nottingham
Lead Sponsor
Kyowa Kirin Pharmaceutical Development Ltd
INDUSTRY